- Home
- PETS vs ELTX Comparison
PETS vs ELTX Comparison
Compare PETS & ELTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PETS | ELTX |
|---|---|---|
| Founded | 1996 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail-Drug Stores and Proprietary Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 63.7M | 141.3M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | PETS | ELTX |
|---|---|---|
| Price | $3.71 | $7.91 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $3.20 | ★ $13.00 |
| AVG Volume (30 Days) | ★ 7.6M | 110.5K |
| Earning Date | 02-02-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $226,972,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.98 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.57 | $4.60 |
| 52 Week High | $5.67 | $12.62 |
Technical Indicators
Market Signals| Indicator | PETS | ELTX |
|---|---|---|
| Relative Strength Index (RSI) | 74.81 | 41.75 |
| Support Level | $1.69 | $7.90 |
| Resistance Level | $4.10 | $8.78 |
| Average True Range (ATR) | 0.36 | 0.66 |
| MACD | 0.26 | 0.02 |
| Stochastic Oscillator | 83.79 | 21.93 |
Price Performance
Historical ComparisonAbout PETS PetMed Express Inc.
PetMed Express Inc along with its subsidiaries is a nationwide pet pharmacy. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats, direct to the consumer. The company generates its revenue by selling pet medications and pet supplies mainly to retail consumers.
About ELTX Elicio Therapeutics Inc.
Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking.